Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 9, 2026, 4:11 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 6,396 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Skin-to-skin Clear all
Completed Phase 2 Interventional Results available

A Study to Test the Efficacy and Safety of SAR442970 in Adults With Hidradenitis Suppurativa

NCT05849922
View directory record Official record
Conditions
Hidradenitis Suppurativa
Interventions
SAR442970, Placebo
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 70 Years
Enrollment
86 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
6
States / cities
Phoenix, Arizona • Ocala, Florida • Tampa, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Jan 28, 2026 · Synced Sep 9, 2026, 4:11 PM EDT
Completed Phase 3 Interventional Results available

Pyridoxine and Topical Urea/Lactic Acid-Based Cream in Preventing Hand-Foot Syndrome in Patients Receiving Capecitabine for Breast Cancer or Other Cancer

NCT00296036
View directory record Official record
Conditions
Breast Cancer, Drug/Agent Toxicity by Tissue/Organ, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
pyridoxine hydrochloride, urea/lactic acid-based topical cream, placebo
Dietary Supplement · Drug · Other
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
137 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2006
U.S. locations
231
States / cities
Scottsdale, Arizona • Aurora, Colorado • Boulder, Colorado + 148 more
Source: ClinicalTrials.gov public record
Updated Mar 15, 2017 · Synced Sep 9, 2026, 4:11 PM EDT
Completed Phase 2 Interventional Results available

Phase IIB TL + YCWP + DC in Melanoma

NCT02301611
View directory record Official record
Conditions
Melanoma
Interventions
TLPLDC, Placebo
Drug
Lead sponsor
Elios Therapeutics, LLC
Industry
Eligibility
18 Years to 99 Years
Enrollment
187 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2022
U.S. locations
18
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 15 more
Source: ClinicalTrials.gov public record
Updated Nov 28, 2024 · Synced Sep 9, 2026, 4:11 PM EDT
Completed Phase 1 Interventional

Study of MEDI0562 Prior to Surgical Resection in Head and Neck Squamous Cell Carcinoma (HNSCC) or Melanoma

NCT03336606
View directory record Official record
Conditions
Head and Neck Cancer, Head and Neck Squamous Cell Carcinoma, Melanoma, Cell Cancer, Squamous, Carcinoma, Squamous Cell
Interventions
MEDI0562
Drug
Lead sponsor
Providence Health & Services
Other
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated May 21, 2026 · Synced Sep 9, 2026, 4:11 PM EDT
Not listed Phase 4 Interventional

Additional Xiaflex® Treatment in Patients With Peyronie's Disease Recurrence, Worsening, or Incomplete Response

NCT03767452
View directory record Official record
Conditions
Peyronie's Disease
Interventions
Xiaflex® 0.58 mg
Drug
Lead sponsor
Manhattan Medical Research Practice, PLLC
Industry
Eligibility
18 Years and older · Male only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 6, 2018 · Synced Sep 9, 2026, 4:11 PM EDT
Completed Phase 2 Interventional

Study of MEDI-507 Administered by Intravenous Infusion to Adults With Plaque Psoriasis

NCT00192452
View directory record Official record
Conditions
Psoriasis
Interventions
MEDI-507
Drug
Lead sponsor
MedImmune LLC
Industry
Eligibility
18 Years to 64 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001
U.S. locations
3
States / cities
Phoenix, Arizona • Winston-Salem, North Carolina • Tacoma, Washington
Source: ClinicalTrials.gov public record
Updated Oct 24, 2006 · Synced Sep 9, 2026, 4:11 PM EDT
Completed Phase 3 Interventional

Efficacy and Safety Study of NeuVax™ (Nelipepimut-S or E75) Vaccine to Prevent Breast Cancer Recurrence

NCT01479244
View directory record Official record
Conditions
Breast Cancer With Low to Intermediate HER2 Expression
Interventions
NeuVax™ vaccine, Leukine® (sargramostim, GM-CSF) and water for injection
Biological
Lead sponsor
Galena Biopharma, Inc.
Industry
Eligibility
18 Years and older · Female only
Enrollment
758 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
81
States / cities
Bessemer, Alabama • Mobile, Alabama • Peoria, Arizona + 65 more
Source: ClinicalTrials.gov public record
Updated Feb 26, 2017 · Synced Sep 9, 2026, 4:11 PM EDT
Terminated Phase 2 Interventional Results available

Topical Sirolimus Ointment for Cutaneous Angiofibromas in Subjects With Tuberous Sclerosis Complex

NCT03363763
View directory record Official record
Conditions
Angiofibroma of Face, Tuberous Sclerosis
Interventions
Sirolimus 0.2%, Sirolimus 0.4%, Placebo ointment
Drug
Lead sponsor
Aucta Pharmaceuticals, Inc
Industry
Eligibility
2 Years to 21 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
7
States / cities
Phoenix, Arizona • Los Angeles, California • Aurora, Colorado + 4 more
Source: ClinicalTrials.gov public record
Updated Nov 30, 2025 · Synced Sep 9, 2026, 4:11 PM EDT
Enrolling by invitation No phase listed Observational

Comparison of Human Allograft to Apligraf for Venous Leg Ulcers

NCT02047084
View directory record Official record
Conditions
Venous Leg Ulcers
Interventions
Not listed
Lead sponsor
Solsys Medical LLC
Industry
Eligibility
21 Years to 90 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2026
U.S. locations
1
States / cities
Greenville, South Carolina
Source: ClinicalTrials.gov public record
Updated Nov 28, 2023 · Synced Sep 9, 2026, 4:11 PM EDT
Completed Phase 3 Interventional

Comparing RadiaPlexRx Hydrogel and Standard-of-Care for Radiation Dermatitis in Breast Cancer Patients

NCT00481884
View directory record Official record
Conditions
Radiation Dermatitis
Interventions
RadiaPlexRx Gel, Aquaphor Gel
Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Female only
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 1, 2016 · Synced Sep 9, 2026, 4:11 PM EDT
Terminated Phase 2 Interventional Results available

Basket Study to Assess Efficacy, Safety and PK of Iptacopan (LNP023) in Autoimmune Benign Hematological Disorders

NCT05086744
View directory record Official record
Conditions
Immune Thrombocytopenia (ITP), Cold Agglutinin Disease (CAD)
Interventions
Iptacopan
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 120 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 15, 2025 · Synced Sep 9, 2026, 4:11 PM EDT
Completed Phase 2 Interventional

Study of NGX267 Oral Capsules in Patients With Xerostomia Associated With Sjorgren's Syndrome

NCT00637793
View directory record Official record
Conditions
Xerostomia, Sjogren's Syndrome
Interventions
NGX267
Drug
Lead sponsor
TorreyPines Therapeutics
Industry
Eligibility
21 Years to 55 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
3
States / cities
Duncansville, Pennsylvania • Philadelphia, Pennsylvania • Austin, Texas
Source: ClinicalTrials.gov public record
Updated Jan 28, 2009 · Synced Sep 9, 2026, 4:11 PM EDT
Completed Not applicable Interventional Results available

NPWT PRO vs KCI Ulta® NPWT and to Compare NPWT PRO vs NPWT PRO With Simultaneous Irrigation on Wound Healing

NCT02519621
View directory record Official record
Conditions
Partial-thickness Burn, Ulcer
Interventions
NPWT PRO without irrigation, NPWT PRO with irrigation, KCI Ulta
Device
Lead sponsor
Larry Lavery
Other
Eligibility
18 Years to 89 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
2
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jul 23, 2023 · Synced Sep 9, 2026, 4:11 PM EDT
Completed Not applicable Interventional Results available

Translating Research Into Practice: Patient Navigation for Breast Cancer

NCT03514433
View directory record Official record
Conditions
Cancer, Breast
Interventions
TRIP Patient Navigation Intervention
Other
Lead sponsor
Boston Medical Center
Other
Eligibility
18 Years and older · Female only
Enrollment
1,725 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2023
U.S. locations
5
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 2, 2024 · Synced Sep 9, 2026, 4:11 PM EDT
Completed Phase 4 Interventional Results available

Vascular Inflammation in Psoriasis Trial (The VIP Trial)

NCT01553058
View directory record Official record
Conditions
Psoriasis, Cardiovascular Disease
Interventions
Adalimumab (Humira), Placebo Injection, NB-UVB phototherapy
Drug · Other
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
97 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
9
States / cities
Sacramento, California • Denver, Colorado • Bethesda, Maryland + 6 more
Source: ClinicalTrials.gov public record
Updated May 21, 2018 · Synced Sep 9, 2026, 4:11 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

A 4-week Study Investigating Two Targeted Brightening Serum (A and B) Versus 4% Hydroquinone in Women With Mild to Severe Full-face Hyperpigmentation

NCT07644871
View directory record Official record
Conditions
Hyperpigmentation, Melasma, Dark Spots
Interventions
Facial Cleanser, Facial Moisturizer, Sunscreen SPF 55
Other
Lead sponsor
Revision Skincare
Industry
Eligibility
20 Years to 60 Years · Female only
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
Irving, Texas
Source: ClinicalTrials.gov public record
Updated Jun 11, 2026 · Synced Sep 9, 2026, 4:11 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Skin Sensitization Test (Modified Draize-95 Test)

NCT03886987
View directory record Official record
Conditions
Skin Sensitisation
Interventions
Blue Non Sterile Powder Free Nitrile Examination Gloves
Device
Lead sponsor
Central Medicare Sdn. Bhd.
Industry
Eligibility
18 Years to 65 Years
Enrollment
245 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Fairfield, New Jersey
Source: ClinicalTrials.gov public record
Updated Mar 21, 2019 · Synced Sep 9, 2026, 4:11 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

A Study to Assess Efficacy and Tolerability of Topical Skincare Products on Psoriasis Patients

NCT06357221
View directory record Official record
Conditions
Plaque Psoriasis, Psoriasis
Interventions
Cetaphil
Drug
Lead sponsor
Galderma R&D
Industry
Eligibility
18 Years and older
Enrollment
46 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
3
States / cities
Columbus, Georgia • Douglasville, Georgia • High Point, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 8, 2026 · Synced Sep 9, 2026, 4:11 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Assistive ExoSkeletons to Enable Wearable Rehabilitation Robotics

NCT03717233
View directory record Official record
Conditions
Diabetic Foot Ulcer, Diabetic Foot Ulcer Associated With Type II Diabetes Mellitus
Interventions
Exoskeleton
Device
Lead sponsor
Results Group LLC
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
2
States / cities
Los Angeles, California • New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Mar 1, 2020 · Synced Sep 9, 2026, 4:11 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Trial to Evaluate Pharmacokinetics, Immunogenicity, Safety, and Tolerability of LEO 138559 in Healthy Japanese Subjects

NCT05099133
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
LEO 138559, LEO 138559 Placebo
Drug
Lead sponsor
LEO Pharma
Industry
Eligibility
18 Years to 65 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Feb 23, 2025 · Synced Sep 9, 2026, 4:11 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study Of The Taste Of Different Oral Liquid Preparations Of CP-690,550 In Trained Adult Product Testers

NCT01023100
View directory record Official record
Conditions
Arthritis, Rheumatoid
Interventions
CP 690,550 oral solutions
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 75 Years
Enrollment
5 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
Woburn, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 15, 2010 · Synced Sep 9, 2026, 4:11 PM EDT
Completed Phase 3 Interventional Results available

Abatacept Versus Adalimumab Head-to-Head

NCT00929864
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Abatacept, Adalimumab
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
869 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
63
States / cities
Birmingham, Alabama • Tuscaloosa, Alabama • Peoria, Arizona + 55 more
Source: ClinicalTrials.gov public record
Updated Feb 3, 2014 · Synced Sep 9, 2026, 4:11 PM EDT
Completed Phase 4 Interventional Results available

A Treatment Regimen for Student Athletes With Mild to Moderate Acne Vulgaris

NCT02249104
View directory record Official record
Conditions
Acne Vulgaris
Interventions
Adapalene/benzoyl peroxide gel, 0.1%/2.5%, Cetaphil Acne Regimen
Drug · Other
Lead sponsor
Galderma R&D
Industry
Eligibility
12 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Pflugerville, Texas
Source: ClinicalTrials.gov public record
Updated Aug 22, 2022 · Synced Sep 9, 2026, 4:11 PM EDT
Active, not recruiting Not applicable Interventional

Testing Home-based Exercise Strategies in Underserved Minority Cancer Patients Undergoing Chemotherapy: the THRIVE Study

NCT05327452
View directory record Official record
Conditions
Breast Cancer, Colorectal Cancer, Prostate Cancer
Interventions
Supervised Home-Based Exercise, Unsupervised Home-Based Exercise, Attention Control
Behavioral
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
135 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 20, 2026 · Synced Sep 9, 2026, 4:11 PM EDT